Avenue Therapeutics Past Earnings Performance
Past criteria checks 0/6
Avenue Therapeutics has been growing earnings at an average annual rate of 19.1%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually.
Key information
19.1%
Earnings growth rate
62.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -154.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Avenue Therapeutics shares slide on pricing $12M securities offering
Oct 07Avenue Therapeutics up 4% on 1-for-15 reverse stock split
Sep 22Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine
Jun 14We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Mar 19
How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?
Jan 23We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Dec 19Avenue Therapeutics issues regulatory update for IV tramadol
Dec 17Revenue & Expenses Breakdown
How Avenue Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -15 | 5 | 6 |
| 31 Mar 24 | 0 | -11 | 5 | 7 |
| 31 Dec 23 | 0 | -10 | 4 | 10 |
| 30 Sep 23 | 0 | -10 | 6 | 10 |
| 30 Jun 23 | 0 | -12 | 6 | 9 |
| 31 Mar 23 | 0 | -8 | 5 | 6 |
| 31 Dec 22 | 0 | -4 | 5 | 3 |
| 30 Sep 22 | 0 | -5 | 3 | 3 |
| 30 Jun 22 | 0 | -5 | 3 | 3 |
| 31 Mar 22 | 0 | -6 | 3 | 3 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -4 | 2 | 1 |
| 30 Jun 21 | 0 | -4 | 2 | 2 |
| 31 Mar 21 | 0 | -5 | 3 | 2 |
| 31 Dec 20 | 0 | -5 | 2 | 3 |
| 30 Sep 20 | 0 | -10 | 2 | 7 |
| 30 Jun 20 | 0 | -11 | 2 | 8 |
| 31 Mar 20 | 0 | -16 | 3 | 14 |
| 31 Dec 19 | 0 | -26 | 3 | 23 |
| 30 Sep 19 | 0 | -24 | 4 | 21 |
| 30 Jun 19 | 0 | -25 | 4 | 21 |
| 31 Mar 19 | 0 | -22 | 4 | 18 |
| 31 Dec 18 | 0 | -22 | 4 | 18 |
| 30 Sep 18 | 0 | -24 | 4 | 20 |
| 30 Jun 18 | 0 | -24 | 4 | 20 |
| 31 Mar 18 | 0 | -22 | 4 | 17 |
| 31 Dec 17 | 0 | -12 | 4 | 8 |
| 30 Sep 17 | 0 | -7 | 3 | 3 |
| 30 Jun 17 | 0 | -4 | 2 | 1 |
| 31 Mar 17 | 0 | -3 | 1 | 1 |
| 31 Dec 16 | 0 | -3 | 1 | 1 |
| 30 Sep 16 | 0 | -4 | 1 | 2 |
Quality Earnings: ATXI is currently unprofitable.
Growing Profit Margin: ATXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATXI is unprofitable, but has reduced losses over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare ATXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATXI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: ATXI has a negative Return on Equity (-154.69%), as it is currently unprofitable.